Professor Ajesh Basantharan Maharaj has become the first researcher at Walter Sisulu University (WSU) to receive a C1 rating from the National Research Foundation (NRF), in a breakthrough reported by IOL on 18 November 2026. The rating, assessed by local and international peers, recognises his sustained productivity, quality and impact in rheumatology research.
For a historically black university in the Eastern Cape, this is more than an individual honour. It is proof that African institutions, long starved of resources by colonial and apartheid planning, can produce scientists whose work stands up to global scrutiny.
Why the NRF C1 rating matters
The National Research Foundation, established as an independent government agency through the National Research Foundation Act of 1998, evaluates researchers based on the quality and impact of their work over time. A C1 rating places Maharaj among researchers whose recent outputs show consistent excellence and international recognition.
WSU said the achievement marks a milestone in its effort to develop researchers whose work earns recognition beyond the institution. The university links the rating to its contribution to the United Nations' Sustainable Development Goal 3, which focuses on healthy lives and well-being for all, and to its Vision 2040+ ambitions under the One Health theme connecting human, animal and environmental health.
Personally, it represents growth, perseverance, and the reward of remaining committed to my goals. Professionally, this achievement reflects my commitment to excellence, continuous development, and maintaining high standards in my work.
Maharaj said the recognition represented both personal and professional growth and motivated him to continue developing his work.
A lone African voice in global rheumatology
As of 2026, Maharaj is the only rheumatologist from sub-Saharan Africa who is a member of the Assessment of Spondyloarthritis International Society (ASAS), an international organisation advancing research and assessment in spondyloarthritis. He also serves as global co-chair of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) comorbidities treatment recommendations committee.
That a single African researcher holds these positions exposes an uncomfortable truth: the continent remains marginal in the global production of medical knowledge, even as its people carry a heavy burden of disease.
Maharaj's work advances the understanding, diagnosis and treatment of rheumatic diseases while insisting that the experiences and healthcare needs of African patients are represented in international research. He explained that psoriatic arthritis is a complex condition requiring input from rheumatology, dermatology, imaging, epidemiology and other fields, and his international collaborations had reinforced the value of working across disciplines.
Against the extraction of African data
Maharaj's research journey has been shaped by the underrepresentation of African patients in global scientific studies. This is the familiar pattern of extractive science: African bodies supply the data, Western institutions keep the authority.
He said African patients needed to be actively involved in generating scientific knowledge about diseases affecting their communities.
I aim to strengthen the African evidence base by advancing research that addresses clinically relevant questions, documents patients' experiences and outcomes in our setting, and contributes African perspectives to international scientific discussions.
He went further, arguing that African researchers should shape global science rather than simply feed it.
Our responsibility as African researchers is not simply to participate in global science, but to help shape it, to generate knowledge that improves the lives of our patients, strengthens our healthcare systems and ensures that Africa is recognised not only as a source of research data, but as a leader in scientific innovation and discovery.
The structural crisis behind the achievement
The milestone lands in a sector in crisis. South Africa and other African countries face shortages of specialist healthcare professionals, delayed diagnoses, limited access to treatment and inadequate research funding in rheumatology.
These gaps are not accidental. They are the living consequence of apartheid's deliberately unequal health system and an academic establishment that still concentrates resources in formerly white institutions. That WSU, named after Walter Sisulu, has produced the university's first C1-rated researcher under these conditions makes the achievement all the more significant.
What comes next
Looking ahead, Maharaj said his ambitions include expanding multicentre research across Africa and helping develop the next generation of African rheumatology researchers. He hopes to help build a sustainable African rheumatology research network that produces evidence relevant to local populations, develops research leaders and influences clinical practice and health policy.
For the African News Agency, which also reported the story, and for the communities WSU serves, the message is clear: the next generation of medical knowledge about African bodies can be produced on African soil, by African hands.
FAQ
What is an NRF C1 rating?
It is a rating awarded by the National Research Foundation to researchers whose recent work shows consistent quality and impact, as evaluated by local and international peers.
Who is Professor Ajesh Maharaj?
He is a rheumatologist at Walter Sisulu University and the first researcher there to receive an NRF C1 rating, recognised for sustained contributions to rheumatic disease research.
Why is this significant for South Africa?
As of 2026, Maharaj is the only sub-Saharan African rheumatologist in ASAS, and his work pushes African patients' needs into international research agendas.
